Raymond W. Cohen has over 25 years of experience in the medical technology field with a career focused on new product development, creation of intellectual property, venture financing, sales and marketing, strategic planning and mergers and acquisitions.
Mr. Cohen is currently the Chief Executive Officer and member of the Board of Directors of Symphony Medical Inc., a venture-capital backed developer of novel biotherapeutic therapies directed toward treating cardiac arrhythmias and congestive heart failure. Cohen also serves as member of the Board of Directors of Cardiac Science Corp., (Nasdaq: CSCX), a global leader in automatic external defibrillators and diagnostic cardiology devices, BioLife Solutions, Inc. (OTC: BLFS) a manufacturer of cryopreservation products used for human cell and tissue preservation, BioGenex, Inc., a manufacturer of diagnostic laboratory instruments for cellular and molecular pathology and Syncroness, Inc., a privately-held contract engineering and product development firm.
Mr. Cohen is a member of a number of local Southern California organizations, notably, the Orange County AeA, the Forum of Corporate Directors, the Young President’s Organization and OCTANe.
In 2008, Mr. Cohen was named by AeA Private Company Life Science CEO of the Year. Mr. Cohen was named Entrepreneur of the Year by the OC Business Journal in 2002 and was a finalist for Ernst & Young Entrepreneur of the Year in the medical company category in 2004.
For the decade prior to 2006, Cohen served as Chairman and Chief Executive Officer of Cardiac Science (Nasdaq: CSCX). In 2004, Cardiac Science was ranked as the 4th fastest growing technology company in North America on Deloitte & Touche’s Fast 500 listing based on its dramatic 5 year growth of over 60,000 percent. From 2002 to 2005, Cardiac Science was ranked #24, #3, #1, and #5 in Deloitte and Touche’s Orange County’s Fast 50 listing. Today, Cardiac Science is a leading developer and manufacturer of diagnostic cardiology systems and automated public-access defibrillators, generates over $200 million in revenue, markets its products in over 70 countries worldwide and has over 500 employees located in offices in the U.S., Denmark and the U.K. During Mr. Cohen’s tenure at Cardiac Science, his company held 77 issued patents and was recognized by Inc. Magazine on “The Innovation 50 – a listing of the most inventive small companies in entrepreneurial America.
Mr. Cohen holds a B.S. in Business Management from the State University of New York at Binghamton and is an Accredited Public Company Director since 2004, having completed the Director Training & Certification Program at the U.C.L.A., Anderson Graduate School of Management.
